Table 2.
Studies Using Two‐Fraction SBRT for Spinal Metastases
| References | Patients (Lesions) | Age (median) | Sex (male/female) | Tumor type | Dose (Gy, median) | Follow‐up (mo, median) | Local control (1‐y) | Overall survival (1‐y) | MINORS |
|---|---|---|---|---|---|---|---|---|---|
| Zeng et al29 | 52 (93) | NA | 27/25 | mixed | 24 | 14.4 and 19.5a | 91.3% | 61.5% | 22 |
| Ito et al30 | 131 (134) | 65 | 81/50 | mixed | 24 | 9 | 72.3% | 65.0% | 12 |
| Ito et al31 | 28 (28) | 62 | 18/10 | mixed | 24 | 13 | 70% | NA | 12 |
| Tseng et al32 | 145 (279) | 68 | 78/67 | mixed | 24 | 15 | 90.3% | 73.1% | 14 |
| Chang et al33 | 60 (72) | 66 | 49/11 | mixed | 24 | 21 | 92% | 90% | 12 |
| Thibault et al34 | 37 (71) | 63 | 25/12 | RCC | 24 | 12.3 | 83% | 64% | 14 |
| Choi et al35 | 42 (51) | 57 | 17/25 | mixed | 20 | 7 | 73% | 68% | 12 |
| Tsai et al36 | 69 (127) | 54 | 34/35 | mixed | 15.5 (mean) | 10 | 96.8% (10‐mo) | NA | 11 |
Abbreviations: Gy: gray; mo: month; NA: not applied; RCC: renal cell carcinoma; y: year.
a
Median follow‐up for cervical cohort and sacral cohort respectively;